Momenta Pharmaceuticals (NASDAQ:MNTA) President Craig Wheeler sold 1,688 shares of the stock on the open market in a transaction dated Thursday, August 15th. The stock was sold at an average price of $15.43, for a total value of $26,045.84. Following the completion of the transaction, the president now directly owns 332,615 shares in the company. The sale was disclosed in a filing with the SEC, which is available at this link.
A number of analysts have recently weighed in on MNTA shares. Analysts at Canaccord Genuity raised their price target on shares of Momenta Pharmaceuticals from $13.00 to $22.00 in a research note to investors on Monday, July 29th. Finally, analysts at UBS AG reiterated a “buy” rating on shares of Momenta Pharmaceuticals in a research note to investors on Monday, July 8th. They now have a $17.00 price target on the stock.
One equities research analyst has rated the stock with a sell rating and three have assigned a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $18.00.
Shares of Momenta Pharmaceuticals (NASDAQ:MNTA) opened at 14.51 on Tuesday. Momenta Pharmaceuticals has a 52 week low of $10.05 and a 52 week high of $18.08. The stock has a 50-day moving average of $15.57 and a 200-day moving average of $14.00. The company’s market cap is $737.3 million.
Momenta Pharmaceuticals (NASDAQ:MNTA) last posted its quarterly earnings results on Thursday, August 1st. The company reported ($0.57) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.45) by $0.12. The company had revenue of $4.40 million for the quarter, compared to the consensus estimate of $8.85 million. During the same quarter in the prior year, the company posted ($0.20) earnings per share. The company’s quarterly revenue was down 79.9% on a year-over-year basis. Analysts expect that Momenta Pharmaceuticals will post $-1.96 EPS for the current fiscal year.
Momenta Pharmaceuticals, Inc (NASDAQ:MNTA) is a biotechnology company specializing in the characterization and process engineering of complex molecules.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.